文献速递流行病学与生物统计临床试验与 GCP

利用肿瘤反应的贝叶斯中介模型预测III期肿瘤试验结局

Predicting outcomes of phase III oncology trials with Bayesian mediation modeling of tumor response.
PubMed 文献 · Stat Med · 2021-12-09

本文提出一个利用贝叶斯中介模型预测III期肿瘤试验结局的框架,预测基于期中分析,对治疗、肿瘤反应及其对生存的联合效应进行多变量建模。该方法可作为不准确试验设计假设的保障,有助于快速终止阴性研究,并可为通过肿瘤反应中介显示生存获益但把握度不足的试验重新估计样本量。方法应用于两项结直肠癌研究,并用模拟评估有无可靠生存替代标志物时的模型表现。

要点

  • 贝叶斯中介模型基于期中分析预测III期肿瘤试验结局,建模治疗、肿瘤反应与生存的关系。
  • 该方法可作为试验前设计假设的保障,可能有助于快速终止阴性研究。
  • 模型可为通过肿瘤反应中介显示生存获益但把握度不足的试验重新估计样本量。

核心结论

  • 利用贝叶斯中介模型预测III期肿瘤试验结局的框架,可作为不准确试验前设计假设的保障,并可能更好地促进阴性研究的快速终止。
  • 该模型可用于为通过肿瘤反应中介显示生存获益但把握度不足的试验重新估计样本量。

研究设计与样本

  • 方法学文章,提出利用贝叶斯中介模型预测III期肿瘤试验结局的框架,预测来自期中分析。
  • 方法应用于两项结直肠癌研究,并使用模拟评估和比较有无可靠生存替代标志物时的模型。

主要发现

  • 预测通过对治疗、肿瘤反应及其对生存的联合效应进行多变量建模得出。
  • 该方法应用于预测两项结直肠癌研究的结局。
  • 模拟用于评估和比较有无可靠生存替代标志物时的模型。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pivotal cancer trials often fail to yield evidence in support of new therapies thought to offer promising alternatives to standards-of-care. Conducting randomized controlled trials in oncology tends to be considerably more expensive than studies of other diseases with comparable sample size. Moreover, phase III trial design often takes place with a paucity of survival data for experimental therapies. Experts have explained the failures on the basis of design flaws which produce studies with unrealistic expectations. This article presents a framework for predicting outcomes of phase III oncology trials using Bayesian mediation models. Predictions, which arise from interim analyses, derive from multivariate modeling of the relationships among treatment, tumor response, and their conjoint effects on survival. Acting as a safeguard against inaccurate pre-trial design assumptions, the methodology may better facilitate rapid closure of negative studies. Additionally the models can be used to inform re-estimations of sample size for under-powered trials that demonstrate survival benefit via tumor response mediation. The methods are applied to predict the outcomes of two colorectal cancer studies. Simulation is used to evaluate and compare models in the absence versus presence of reliable surrogate markers of survival.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Zhou J, Jiang X, Xia HA, et al. Predicting outcomes of phase III oncology trials with Bayesian mediation modeling of tumor response. Stat Med. 2021. PMID: 34888892. doi:10.1002/sim.9268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。